Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Skytrofa
Pharma
Ascendis must wait 3 more months for FDA verdict on TransCon PTH
It’s been a long wait for Ascendis to score FDA approval for its hormone replacement therapy TransCon PTH. Now, it’ll take another three months.
Kevin Dunleavy
May 14, 2024 5:36pm
Royalty Pharma strikes $150M Skytrofa royalty deal with Ascendis
Sep 6, 2023 11:28am
Pfizer, Opko gain FDA nod for weekly growth hormone drug Ngenla
Jun 28, 2023 10:42am
Pfizer’s rare disease plan takes surprising hit
Jan 24, 2022 10:19am
